Glucose Transporter Glut8 CRISPR Activation Plasmid (h): sc-403183-ACT

SLC2A8 encodes the facilitative glucose transporter GLUT8, an intracellular and plasma membrane-associated carrier that contributes to hexose uptake and redistribution in metabolically active cells. GLUT8 supports cellular energy homeostasis by regulating glucose availability for glycolysis, glycogen metabolism, and broader nutrient-sensing programs, integrating with pathways that coordinate insulin responsiveness and organelle trafficking. Altered SLC2A8 expression or localization has been investigated in contexts of metabolic dysregulation, oxidative stress responses, and tissue-specific fuel utilization. In biomedical research, GLUT8 is used to probe how transporter abundance and compartmentalization shape cell growth, differentiation, and substrate preference.

Glucose Transporter Glut8 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous SLC2A8 expression without altering the underlying DNA sequence.

Glucose Transporter Glut8 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the SLC2A8 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.

Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the SLC2A8 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Glucose Transporter Glut8 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native SLC2A8 locus and enabling the study of Glucose Transporter Glut8-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Glucose Transporter Glut8 pathway restoration in tumor cells with silenced or reduced SLC2A8 expression.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.